Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
STERITALC vs SOTRADECOL
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Sterile talc (STERITALC) induces pleural inflammation and fibrosis, leading to adhesion of the pleural layers. This mechanism is mediated by activation of mesothelial cells and fibroblasts, resulting in release of inflammatory cytokines and growth factors.
Sotradecol (sodium tetradecyl sulfate) is a sclerosing agent that acts by irritating the intimal endothelium of veins, causing inflammation, thrombosis, and subsequent fibrosis, leading to occlusion of the treated vein.
Pleurodesis for malignant pleural effusion,Pleurodesis for recurrent pneumothorax,Pleurodesis for chylothorax (off-label)
Uncomplicated spider veins (telangiectasias) and reticular veins of the lower extremities,Small, uncomplicated varicose veins
Sterile talc powder for intrapleural administration: 4-8 g mixed with 50-250 m L normal saline, instilled via chest tube for pleurodesis. Single dose typically used.
0.5 m L per injection site, multiple sites per session; maximum volume 10 m L per session; intravenous (sclerotherapy) administration; frequency every 4-6 weeks.
Not applicable; talc particles are not metabolized and remain in the pleural space indefinitely, with gradual clearance over months to years via macrophage uptake and lymphatic drainage.
Terminal elimination half-life approximately 5-6 hours; clinical effect persists longer due to local action at injection site
Talc is an inert mineral; not metabolized. Systemic absorption may lead to deposition in tissues, but no specific metabolic pathway exists.
Sodium tetradecyl sulfate is primarily metabolized in the liver via sulfation and glucuronidation, with involvement of hepatic enzymes such as sulfotransferases and UDP-glucuronosyltransferases (UGTs).
Sterile talc (STERITALC) is not absorbed systemically following intrapleural administration. Excretion occurs locally via phagocytosis and clearance by pleural lymphatics; no significant renal, biliary, or fecal elimination applies.
Primarily renal; <1% recovered as unchanged drug in urine; majority eliminated as metabolites via bile into feces
Not applicable; talc is an inorganic silicate, does not bind to plasma proteins.
>90% bound to plasma proteins, primarily albumin
Not applicable; talc remains at the site of administration (pleural space) with negligible systemic distribution.
0.15-0.3 L/kg; reflects limited distribution primarily to plasma and interstitial space
Not applicable; administered via intrapleural instillation and acts locally. No systemic absorption is intended or occurs.
Not applicable; administered via intradermal, intravenous, or endoscopic injection; not intended for oral administration
No dose adjustment required for renal impairment.
No specific dose adjustment provided in labeling; not studied in renal impairment; use caution in severe impairment.
No dose adjustment required for hepatic impairment.
No specific dose adjustment provided in labeling; caution in Child-Pugh class C due to potential for acute hepatic necrosis.
Safety and efficacy not established in pediatric patients; use not recommended.
Safety and efficacy not established in pediatric patients (age <18 years).
No specific dose adjustment; consider general precautions for elderly due to potential comorbidities.
No specific dose adjustment required; consider comorbidities and overall health status.
Risk of acute respiratory distress syndrome (ARDS), pneumonitis, and granulomatous inflammation secondary to talc particle absorption. Use only as a sterile, asbestos-free talc slurry or poudrage. Avoid systemic absorption.
Sotradecol injection is contraindicated for the treatment of patients with underlying arterial disease or with known allergy to the drug. Severe adverse reactions including anaphylaxis, pulmonary embolism, and tissue necrosis have been reported.
Use only sterile, asbestos-free talc,Monitor for respiratory distress, pneumothorax, or re-expansion pulmonary edema,Avoid in patients with empyema or active pleural infection,Caution in patients with compromised pulmonary function,Risk of fever, chest pain, and pleural effusion recurrence
Anaphylactic reactions; arterial injection causing tissue necrosis; pulmonary embolism; allergy to the drug; use with caution in patients with thrombophlebitis, hypercoagulable states, or chronic obstructive pulmonary disease; avoid extravasation.
Hypersensitivity to talc,Pleural infection or empyema,Severe respiratory insufficiency,Pregnancy and lactation (relative contraindication),Uncontrolled bronchopleural fistula
Known allergy to sodium tetradecyl sulfate; acute thrombophlebitis; severe chronic venous insufficiency; arterial disease; uncontrolled diabetes mellitus; sepsis; pregnancy; breastfeeding; incompetent perforating veins.
No known food interactions. Maintain normal diet unless otherwise instructed by physician.
No specific food interactions are known. Patients should maintain adequate hydration and avoid excessive alcohol intake, which may increase the risk of bleeding or thrombosis. No dietary restrictions are required.
Insufficient human data; animal studies not conducted. Sterile talc is not absorbed systemically when used for pleurodesis, thus minimal fetal exposure. However, talc may cause maternal inflammation and fever, which could theoretically increase risk of preterm labor or fetal distress in third trimester. Use in pregnancy only if clearly needed.
FDA Pregnancy Category C. No adequate human studies; animal studies show fetal harm. Use only if benefit outweighs risk. First trimester: potential teratogenicity. Second/third trimester: risk of fetal bradycardia, arrhythmias, or death due to systemic absorption if injected near cervix.
No data on excretion into breast milk. Due to lack of systemic absorption after pleural administration, transfer into milk is unlikely. Caution advised; consider risk-benefit.
Unknown excretion in human milk. Due to low systemic absorption after local injection, risk to breastfed infant is likely low. Caution recommended; M/P ratio not established.
No dose adjustment necessary due to minimal systemic absorption. Use standard pleurodesis dose (typically 2-5 g as slurry or poudrage).
No dose adjustment required; however, use only when clearly needed. Systemic absorption is minimal after local injection, and pharmacokinetic changes in pregnancy are unlikely to alter efficacy or safety.
STERITALC (talc) is used for pleurodesis in malignant pleural effusion or recurrent pneumothorax. Administer via chest tube as a slurry or poudrage. Monitor for chest pain, fever, and hypoxia post-instillation. Ensure lung re-expansion before use to avoid trapped lung. Do not use in patients with empyema or bronchopleural fistula.
Sotradecol (sodium tetradecyl sulfate) is a sclerosing agent used for the treatment of varicose veins. Administer via direct injection into the vein using a fine needle; avoid extravasation as it causes tissue necrosis. Perform a test dose (0.5 m L) to assess for hypersensitivity. Compression stockings should be worn for 1-3 weeks post-injection. Do not exceed 10 m L per session; maximum total dose per session is 10 m L of 1% or 2 m L of 3% solution. Use caution in patients with arterial disease, recent thrombosis, or known hypersensitivity. Delayed skin pigmentation may occur. Allergic reactions, including anaphylaxis, have been reported.
You may experience chest pain, fever, or shortness of breath after the procedure.,The medication causes the layers of your lung to stick together to prevent fluid or air buildup.,Report any severe pain, difficulty breathing, or signs of infection immediately.,Avoid strenuous activity and keep the chest tube site clean and dry.,Follow up with your doctor for imaging to confirm pleurodesis effectiveness.
This medication is injected directly into your varicose veins to cause them to collapse and fade.,You may experience a burning sensation at the injection site, which is normal.,Wear compression stockings as directed, typically for 1-3 weeks after treatment.,Avoid strenuous exercise and prolonged standing for 24-48 hours after injection.,Contact your doctor if you develop severe pain, swelling, redness, or skin ulcers at the injection site.,Notify your doctor if you have a history of blood clots, allergies, or are pregnant or breastfeeding.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about STERITALC vs SOTRADECOL, answered by our medical review team.
STERITALC is a Sclerosing Agent that works by Sterile talc (STERITALC) induces pleural inflammation and fibrosis, leading to adhesion of the pleural layers. This mechanism is mediated by activation of mesothelial cells and fibroblasts, resulting in release of inflammatory cytokines and growth factors.. SOTRADECOL is a Sclerosing agent that works by Sotradecol (sodium tetradecyl sulfate) is a sclerosing agent that acts by irritating the intimal endothelium of veins, causing inflammation, thrombosis, and subsequent fibrosis, leading to occlusion of the treated vein.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between STERITALC and SOTRADECOL depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of STERITALC is: Sterile talc powder for intrapleural administration: 4-8 g mixed with 50-250 m L normal saline, instilled via chest tube for pleurodesis. Single dose typically used.. The standard adult dose of SOTRADECOL is: 0.5 m L per injection site, multiple sites per session; maximum volume 10 m L per session; intravenous (sclerotherapy) administration; frequency every 4-6 weeks.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between STERITALC and SOTRADECOL in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. STERITALC is classified as Category C. Insufficient human data; animal studies not conducted. Sterile talc is not absorbed systemically when used for pleurodesis, thus minimal fetal exposure. However, talc may cause mat. SOTRADECOL is classified as Category C. FDA Pregnancy Category C. No adequate human studies; animal studies show fetal harm. Use only if benefit outweighs risk. First trimester: potential teratogenicity. Second/third tri. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.